Pharmaceutical Commerce - December 2024

Click the title above for a link to open the Pharmaceutical Commerce December 2024 issue in an interactive PDF format.

Our December analysis of the twists and turns in the Drug Supply Chain Security Act is a timely one, as the FDA recently again pushed back the deadline for complying with new mandates on tracking and tracing drugs at the package level.

The value of this sometimes-unheralded technology to the pharma industry—as well as potential use cases—are starting to come to light.

Access Insights Conference delves into the latest obstacles, while mapping out potential solutions to address them.

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Filling the gaps in the patient journey within an increasingly complex data environment.

A guide to overcoming the top obstacles facing patient services programs today.

The importance of embracing universal values and business models that prioritize humanity.

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good idea?

While the program could be a good option for many, it's not a panacea.

A crash course on the bubble itself, including therapeutic areas most affected.

It’s essential for commercial success, but presents its share of obstacles.